SCHEDULE: Vanguard Group Amends PacBio Holdings to Zero Post-Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Pacific Biosciences of California Inc following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 4 to Schedule 13G for Pacific Biosciences of California Inc.
• The filing reports 0 shares beneficially owned by The Vanguard Group, representing 0% of the Common Stock class.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing for Pacific Biosciences of California Inc, as it primarily reflects an internal organizational change by The Vanguard Group rather than a direct investment or divestment decision impacting the issuer.

Positives

• The Vanguard Group is adhering to SEC Release No. 34-39538 (January 12, 1998) by disaggregating beneficial ownership reporting, demonstrating regulatory compliance.

Negatives

• The Vanguard Group, Inc. no longer holds beneficial ownership of Pacific Biosciences of California Inc common stock, which could be interpreted as a reduction in institutional interest from the parent entity, though the underlying holdings may still exist within its subsidiaries.

Risks

• NA

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like The Vanguard Group are not uncommon and typically reflect internal operational or regulatory compliance adjustments rather than a change in investment thesis regarding the underlying issuer. The disaggregation of reporting allows for more granular transparency from individual funds or divisions.

Stakeholder Impact

• Shareholders of Pacific Biosciences of California Inc: May see a change in the reported institutional ownership by The Vanguard Group, though the underlying investment by Vanguard's subsidiaries may persist.
• The Vanguard Group's investors: Will see more granular reporting of beneficial ownership from specific subsidiaries/divisions.

Next Steps

• Subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately for Pacific Biosciences of California Inc.

Key Dates

Recommendation

The filing is a technical update regarding an institutional investor's internal reporting structure and does not provide new information about Pacific Biosciences of California Inc's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Pacific Biosciences, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Realignment